BREAKING: An influential federal advisory panel rejected a plan to offer Pfizer booster shots against COVID-19 to most Americans. The 16-2 vote was a blow to the Biden administration’s effort to increase virus protections amid the contagious delta variant.
The vote by the committee of outside experts assembled by the Food and Drug Administration was 16-12, with members expressing frustration that Pfizer had provided little data on the safety of extra doses. Many also raised doubts about the value of mass boosters, rather than ones targeted to specific groups.
Dr. Amanda Cohn of the Centers for Disease Control and Prevention said: “At this moment it is clear that the unvaccinated are driving transmission in the United States.” The FDA advisory panel was the first major hurdle that the Biden administration plan faced. The FDA itself has yet to make its own determination but typically follows the recommendations of its expert panel.
Sharon Alroy-Preis of Israel’s Ministry of Health said the booster dose improves protection tenfold against infection in people 60 and older. Pfizer pointed to Israeli data from nearly 3 million boosters to suggest side effect rates would be similar to that seen after second doses. But that was before FDA staff scientists had completed their own assessments of the data. Some experts questioned whether Biden was breaking his own pledge to “follow the science” on COVID-19 by getting out ahead of government scientists.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
FDA Questions Need For Pfizer Covid-19 Booster Shot Ahead Of Vote FridayScientists at the FDA said Pfizer’s Covid-19 vaccine seems to last long enough that a booster shot may not add much protection
Weiterlesen »
FDA Questions Need For Pfizer Covid-19 Booster Shot Ahead Of Vote FridayScientists at the FDA said Pfizer’s Covid-19 vaccine seems to last long enough that a booster shot may not add much protection
Weiterlesen »
FDA advisers vote to oppose Pfizer/BioNTech COVID-19 vaccine boosterA panel of outside advisers to the U.S. Food and Drug Administration on Friday voted against approval of a booster dose of the Pfizer Inc /BioNTech SE COVID-19 vaccine for people aged 16 and older.
Weiterlesen »
What to expect as FDA advisory panel debates Pfizer COVID booster shotsThe FDA's independent advisory committee is convening to review data submitted by Pfizer and discuss whether a booster dose is safe enough for widespread use and whether it's necessary and effective at improving protection levels against COVID-19.
Weiterlesen »
Pfizer says third COVID shot gives antibodies in threefold, likely can handle Delta variantThe FDA on Wednesday posted much of the evidence from Pfizer on booster shots to be considered by its advisory panel on Friday.
Weiterlesen »
US govt advisers vote no to Pfizer Covid boosters for ages 16 and upLeading US medical experts advising the government voted against recommending booster doses of Pfizer's COVID-19 vaccine for everyone aged 16 and up, citing concerns about potential side-effects in younger age groups.
Weiterlesen »